CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Nortriptyline",CYP2D6,Major – significant result that may require altering this medication
"Pantoprazole",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
"Ibuprofen",CYP2C9,Usual prescribing considerations apply
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"acetaminophen, nifedipine, azathioprine, ranitidine, valsartan",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG3
"",Propafenone,CYP2D6,Adverse effects,DPWG3
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Significantly increasedacenocoumarol sensitivity",DPWG
"",Warfarin,"VKORC1CYP2C9","Significantly increased warfarinsensitivity",FDA4
"Antidepressants -SSRIs",Citalopram,CYP2C19,Reduced / inadequate response,CPIC5
"",Escitalopram,CYP2C19,Reduced / inadequate response,CPIC5
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19",Altered response,CPIC1
Clomipramine,"CYP2D6CYP2C19",Altered response,CPIC1,
Desipramine,CYP2D6,Adverse effects,CPIC1,
Doxepin,"CYP2D6CYP2C19",Altered response,CPIC1,
Imipramine,"CYP2D6CYP2C19",Altered response,CPIC1,
Nortriptyline,CYP2D6,Adverse effects,CPIC1,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antifungals - Azoles,Voriconazole,CYP2C19,Reduced / inadequate response,CPIC6
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG3
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC7
Opioid Analgesics,Codeine,"CYP2D6OPRM1",Reduced / inadequate response,CPIC8
Tramadol,CYP2D6,Reduced / inadequate response,DPWG3,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,-
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,Adverse effects,-
"",Fesoterodine,CYP2D6,Adverse effects,-
"",Tolterodine,CYP2D6,Adverse effects,-
Anticholinesterases,Donepezil,CYP2D6,Adverse effects,-
"",Galantamine,CYP2D6,Adverse effects,-
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2",Adverse effects,-
"",Moclobemide,CYP2C19,Reduced / inadequate response,-
"",Vortioxetine,CYP2D6,Adverse effects,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2",Adverse effects,-
"",Venlafaxine,CYP2D6,Adverse effects,DPWG3
"Antidepressants -SSRIs",Fluoxetine,"CYP2D6CYP2C9",Altered response,-
"",Fluvoxamine,"CYP2D6CYP1A2",Adverse effects,CPIC5
"",Paroxetine,CYP2D6,Adverse effects,CPIC5
"",Sertraline,CYP2C19,Reduced / inadequate response,CPIC5
Antidiabetics,Gliclazide,"CYP2C9CYP2C19",Reduced / inadequate response,-
Antiemetics,Metoclopramide,CYP2D6,Adverse effects,-
"",Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC9
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
"",Promethazine,CYP2D6,Adverse effects,-
Antiplatelet drugs,Clopidogrel,CYP2C19,Adverse effects,CPIC10
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,-
"",Brexpiprazole,CYP2D6,Adverse effects,-
"",Chlorpromazine,CYP2D6,Adverse effects,-
"",Haloperidol,CYP2D6,Adverse effects,-
"",Pimozide,CYP2D6,Adverse effects,
"",Risperidone,CYP2D6,Adverse effects,DPWG3
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG3
Antitussives,Dextromethorphan,CYP2D6,Adverse effects,-
Benzodiazepines,Clobazam,CYP2C19,Reduced / inadequate response,-
"",Diazepam,CYP2C19,Reduced / inadequate response,-
Beta blockers,Carvedilol,CYP2D6,Adverse effects,-
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Nebivolol,CYP2D6,Adverse effects,-
"",Propranolol,"CYP2D6CYP1A2",Adverse effects,-
"Glaucoma - ocularpreparations",Timolol,CYP2D6,Adverse effects,-
Miscellaneous,Cyclophosphamide,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Eliglustat,CYP2D6,Adverse effects,TGA11
"",Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
"",Proguanil,CYP2C19,Altered response,-
Neurological drugs,Tetrabenazine,CYP2D6,Adverse effects,FDA12
Opioid Analgesics,Hydrocodone,CYP2D6,Altered response,
"",Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"",Oxycodone,CYP2D6,Reduced / inadequate response,DPWG3
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,Reduced / inadequate response,-
"",Esomeprazole,CYP2C19,Reduced / inadequate response,-
"",Lansoprazole,CYP2C19,Reduced / inadequate response,-
"",Omeprazole,CYP2C19,Reduced / inadequate response,-
"",Pantoprazole,CYP2C19,Reduced / inadequate response,-
"",Rabeprazole,CYP2C19,Reduced / inadequate response,-
Psychostimulants,Dextroamphetamine,CYP2D6,Adverse effects,-
Lisdexamfetamine,CYP2D6,Adverse effects,-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"No altered effect predicted bygenotype",-
"",Losartan,CYP2C9,"No altered effect predicted bygenotype",-
Antidiabetics,Glimepiride,CYP2C9,"No altered effect predicted bygenotype",-
"",Glyburide,CYP2C9,"No altered effect predicted bygenotype",-
Antiepileptics,Phenytoin,CYP2C9,"No altered effect predicted bygenotype",CPIC13
Antipsychotics,Clozapine,CYP1A2,"No altered effect predicted bygenotype",-
"",Olanzapine,CYP1A2,"No altered effect predicted bygenotype",-
"",Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC14
Hypnotics,Melatonin,CYP1A2,"No altered effect predicted bygenotype",-
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
NSAIDs,Celecoxib,CYP2C9,"No altered effect predicted bygenotype",-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"",Diclofenac,CYP2C9,"No altered effect predicted bygenotype",-
"",Flurbiprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Ibuprofen,CYP2C9,"No altered effect predicted bygenotype",-
"",Indomethacin,CYP2C9,"No altered effect predicted bygenotype",-
"",Mefenamic Acid,CYP2C9,"No altered effect predicted bygenotype",-
"",Meloxicam,CYP2C9,"No altered effect predicted bygenotype",-
"",Piroxicam,CYP2C9,"No altered effect predicted bygenotype",-
Statins,Atorvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",-
Fluvastatin,"SLCO1B1CYP2C9","No altered effect predicted bygenotype",-,
Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
Simvastatin,"SLCO1B1CYP3A4","No altered effect predicted bygenotype",CPIC15,
